Annuncio • Aug 20
The Precision Peptide Company Inc. Announces Development of Needle-Free Tirzepatide Transdermal Patch The Precision Peptide Company Inc. announced that the Company is developing a tirzepatide-based transdermal patch delivery system in the United States as an addition to its advancing product lineup. The Precision Peptide Company's transdermal patch under development is intended to eliminate the need for injections and cold-chain storage that most current tirzepatide products require. All of the Company's development and intended manufacturing will be conducted in the U.S. in compliance with applicable regulatory requirements, including FDA standards. As part of the Company's strategy to build a next-generation platform for high-quality peptide formulations and consumer-friendly delivery technologies, the Company is developing a needle-free tirzepatide transdermal patch designed to deliver tirzepatide through the skin without injection. The transdermal patch is under development and is intended to complement the Company's existing and advancing product lineup. Tirzepatide is a dual GIP/GLP-1 receptor agonist, a synthetic peptide that activates two key metabolic receptors involved in blood sugar regulation, appetite, and energy balance. It was originally developed for the management of type 2 diabetes and has more recently become a widely used treatment for chronic obesity and weight management. Tirzepatide products currently available to consumers are administered as once-weekly subcutaneous injections and require refrigerated storage at 2 to 8°C (36 to 46°F), with only a limited room-temperature window before the product must be discarded. The Company believes there is demand for an alternative delivery method that removes the barriers of needles, cold-chain logistics, and sharps disposal. The Majority of tirzepatide treatments available to consumers require once-weekly self-administered injections, refrigerated storage, and sharps disposal. The Company believes that a needle-free transdermal patch could address several barriers to therapy initiation and long-term adherence: Needle avoidance: A 2019 global systematic review and meta-analysis published in the Journal of Advanced Nursing reported needle-fear prevalence of approximately 20 to 30% among adults aged 20 to 40 years, declining with age. Needle fear is a well-documented barrier to initiating injectable therapies. A transdermal patch is designed to address this barrier. No refrigeration required: Current injectable tirzepatide products are stored at 2 to 8°C, with only a limited room-temperature window. The Company's transdermal patch is being developed with the goal of room-temperature stability, which would eliminate cold-chain logistics for patients, pharmacies, and distributors. Travel friendly: A transdermal patch is intended to be discreet and portable, with no need for sharps disposal containers or refrigerated travel cases. Better adherence potential: With a significant proportion of patients discontinuing injectable GLP-1 therapy within the first year, the Company believes that a simpler, less invasive delivery method could improve long-term treatment outcomes, though there can be no assurance of this. Tirzepatide products (Mounjaro and Zepbound, marketed by Eli Lilly and Company) generated combined sales of approximately USD 36,500 million in 2025. The broader global GLP-1 receptor agonist market was valued at approximately USD 62,000 million to USD 66,000 million in 2025 and is projected to grow to USD 185,300 million by 2033. According to Gallup, approximately 11% of U.S. adults reported using a GLP-1 medication for weight loss as of mid-2026, more than triple the rate measured two years earlier. Despite this growing demand, real-world persistence on GLP-1 therapy for obesity remains a challenge, with research suggesting that a significant proportion of patients discontinue treatment within the first year. Development of the Company's tirzepatide transdermal patch is being conducted in the United States. The Company intends all products to be manufactured in the United States in compliance with applicable regulatory requirements, including FDA standards. The development of a needle-free transdermal delivery system is consistent with the Company's broader mission to responsibly develop peptide therapies for the public through regulatory-compliant and consumer-friendly delivery systems. Annuncio • Aug 01
The Precision Peptide Company Announces Seven Products Now Available Including The Recovery Patch The Precision Peptide Company announced that seven products are in stock and available for direct purchase across all 50 U.S. states. Seven products are listed in stock across capsules, a topical serum and a transdermal patch. The Recovery Patch is a transdermal peptide patch formulated for active individuals and is the Company's first patch product available at retail. It is applied directly to the skin and requires no mixing, no measurement and no refrigeration. Additional patch formats remain in development. BPC capsules are formulated to support recovery processes. KPV capsules are formulated for daily support of gut comfort, inflammatory response and skin appearance. Ageless capsules are formulated to support the body's repair and energy systems with aging. Chill capsules are formulated to support calm and restful sleep without melatonin. Blue capsules provide cellular energy support mental clarity and focus without caffeine. Hair is a copper-peptide serum formulated for scalp condition and the appearance of fuller hair. Products are manufactured to Current Good Manufacturing Practice (“cGMP”) standards and third-party tested for purity, potency and identity. The platform is supported by the previously announced LegitScript Healthcare Merchant Certification. The certification independently supports compliance and consumer-safety standards and positions the Company to process payments and conduct marketing activities across major payment and advertising platforms. The retail catalogue operates alongside the U.S. compounding and telehealth infrastructure announced earlier this year, including the Company's 503A compounding agreement and telehealth platform. GLP-1, Sermorelin and NAD+ protocols are listed on the platform as coming soon and would be delivered through that prescription pathway. No timeline for their availability has been established. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides and voted in favour of six for consideration on the 503A Bulks List. BPC-157, KPV, thymosin beta-4 and MOTS-c were supported on the first day, and semax and epitalon on the second. One substance was not recommended. Four of the six supported peptides are used in formulations within the Company's existing portfolio. An advisory committee recommendation is not FDA approval. The votes are non-binding, the FDA is not required to follow them, and any addition to the 503A Bulks List requires a separate formal rulemaking process with an uncertain outcome and timeline. The 503A Bulks List governs pharmacy compounding and does not apply to the over-the-counter products the Company sells at retail. Annuncio • Jul 29
The Precision Peptide Company Advances Testing of Thymosin Alpha-1 Transdermal Patch for Immune Support The Precision Peptide Company announced that testing is underway for its Thymosin Alpha-1 transdermal patch. Testing is focused on formulation stability and performance within the patch format and is targeted for completion in Third Quarter/Fourth Quarter 2026. Based on its review of currently available products, The Precision Peptide Company believes the product could be among the first commercially available Thymosin Alpha-1 transdermal patches. Thymosin Alpha-1 is a naturally occurring peptide that has been studied for its immune-modulating properties. A Fiscal year 2025 systematic review and meta-analysis examined its role in immune regulation, inflammation and infection-related outcomes, demonstrating continued scientific interest in its potential immune-related applications. The study did not evaluate The Precision Peptide Company’s patch, which remains under development and testing. The patch is a consumer wellness product and has not been evaluated by the U.S. Food and Drug Administration or Health Canada. It is not intended to diagnose, treat, cure, or prevent any disease. Thymosin Alpha-1 has traditionally been associated with injectable administration. The Precision Peptide Company is developing the transdermal patch as a portable, needle-free alternative that can be applied directly to the skin without mixing, preparation or cold storage. The format is intended to make Thymosin Alpha-1 easier to transport and incorporate into daily wellness routines. It also supports The Precision Peptide Company’s broader strategy of converting peptide ingredients into convenient, consumer-ready formats. The Company's development approach targets three key functions; stabilization of the peptide formulation, permeation through the skin and sustained release over time. The patch is being formulated and tested in the United States, supporting The Precision Peptide Company’s focus on U.S.-based product development and manufacturing. Current testing will evaluate whether Thymosin Alpha-1 can be maintained in a stable patch formulation and delivered consistently through the intended transdermal format. Completion is targeted for Third Quarter/Fourth Quarter 2026. Subject to successful testing, the product would expand The Precision Peptide Company’s transdermal portfolio into the immune-support category and provide another potential commercial application for its delivery platform. The Thymosin Alpha-1 program builds on The Precision Peptide Company’s broader work in transdermal delivery and its focus on stabilization, permeation and sustained-release applications. The patch portfolio is being developed to address recovery, immunity and other targeted wellness categories through formats intended to be simpler and more portable than conventional administration methods. The Company’s broader strategy centers on quality consumer-ready accessible peptide formats. Annuncio • Jul 24
U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee Recommends Bpc-157 and Kpv to Be Considered for Inclusion on 503A Bulks List The Precision Peptide Company Inc. applauded vote by the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (the "Committee"), which recommended that BPC-157 and KPV (Lysine-Proline-Valine) be considered for inclusion on the FDA's 503A Bulks List. While the recommendation is advisory and subject to final FDA review, the Company believes it represents a positive step toward improving patient access to quality-focused, professionally compounded peptide therapies. If ultimately adopted by the FDA, this day's advisory committee recommendation represents a significant step toward allowing U.S. patients to legally access physician-prescribed BPC-157 through regulated compounding pharmacies, replacing much of the current reliance on unregulated sources. KPV, like BPC-157, has received a favourable FDA advisory-committee recommendation for inclusion on the 503A Bulks List and is now advancing through the FDA's regulatory process. It has not yet received FDA approval or final list inclusion. This comes shortly after the Company's news release dated July 14, 2026 highlighting that the Company received a 20,000-unit production run of its BPC-157 transdermal patch. The patches are manufactured and independently tested in the United States and marks the Company's transition from testing to commercialization. Each patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results, which confirmed 95.5% chromatographic purity, exceeding the 95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch. The Committee's decision reflects the growing recognition that patients and healthcare providers are seeking regulated, pharmacy-compounded alternatives to an unregulated gray market. By supporting a more structured regulatory pathway, the FDA has the opportunity to enhance patient safety, quality standards, and oversight while encouraging continued scientific and clinical evaluation of peptides such as BPC-157 & KPV. The Precision Peptide Company remains committed to developing pharmaceutical-grade peptide products through rigorous manufacturing, quality assurance, and evidence-based innovation. As the regulatory landscape continues to evolve, the Company looks forward to supporting responsible commercialization efforts that prioritize patient safety, physician oversight, and product quality. Annuncio • Jul 15
The Precision Peptide Company Receives 20,000-Unit Production Run Of BPC-157 Transdermal Patches The Precision Peptide Company has received its production run of approximately 20,000 units of its BPC-157 transdermal patch, the Company's lead product candidate. The arrival of this commercial inventory follows the Company's previously announced order and represents a key step in the Company's transition from testing and formulation validation to commercialization. The Patch is manufactured in the United States and was independently tested by a U.S. analytical laboratory. Each Patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results reported in the Company's previous news release, which confirmed 95.5% chromatographic purity, exceeding the =95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch. With commercial inventory now in hand, the Company is positioned to proceed toward the initial commercial release of the Patch. Annuncio • Jul 03
The Precision Peptide Company Inc Announces Appointment of Diane Stafrace to Advisory Board The Precision Peptide Company Inc. appointed Diane Stafrace to its Advisory Board. Stafrace is a Certified Peptide Therapist and Integrative Health Coach based in Vancouver, British Columbia, whose practice sits at the intersection of peptide science, integrative nutrition, and behavior change. Stafrace is the founder of Get Set by Diane, a Vancouver-based integrative health practice where she designs personalized peptide protocols and wellness programs for clients focused on performance, recovery, longevity, and overall well-being. Her work spans peptide therapy consulting, GLP-1 support, personalized nutrition, and behavior change coaching, with a core philosophy centered on addressing root causes rather than symptoms and building wellness habits that last. Her credentials include Certification in Peptide Therapy from Empowered Academy USA, Certified Integrative Health Coach from the Institute for Integrative Nutrition (IIN), Certified Personal Trainer and Behaviour Change Specialist from the National Academy of Sports Medicine (NASM), and a B.Sc. in Mass Communications from the University of Malta. Earlier in her career, she spent five years as a medical representative, building a foundation in the OTC and broader healthcare sector that continues to inform her integrative approach. Known for a personalized, whole-person approach to health, Stafrace works closely with clients to deliver lasting, meaningful results across performance, recovery, and longevity. Her perspective is expected to support Precision Peptides continued consumer education efforts as the market for peptide-based wellness solutions expands. 
